Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMTNASDAQ:BBIONASDAQ:BPMCNASDAQ:CORT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/ABBIOBridgeBio Pharma$41.73+4.3%$36.11$21.62▼$41.94$7.92B1.12.52 million shs5.53 million shsBPMCBlueprint Medicines$128.20+0.1%$104.75$73.04▼$128.34$8.28B0.841.26 million shs4.51 million shsCORTCorcept Therapeutics$71.38+0.2%$71.56$29.42▼$117.33$7.57B0.191.14 million shs1.74 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%BBIOBridgeBio Pharma0.00%+4.90%+26.57%+20.02%+51.14%BPMCBlueprint Medicines0.00%+0.19%+27.77%+44.50%+20.14%CORTCorcept Therapeutics0.00%+1.88%-6.19%+21.68%+153.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABBIOBridgeBio Pharma4.5358 of 5 stars4.52.00.03.92.03.30.6BPMCBlueprint Medicines0.9954 of 5 stars2.12.00.00.01.90.80.6CORTCorcept Therapeutics4.6161 of 5 stars3.51.00.04.22.94.21.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune Therapeutics 0.00N/AN/AN/ABBIOBridgeBio Pharma 2.92Moderate Buy$56.6735.79% UpsideBPMCBlueprint Medicines 2.27Hold$128.06-0.11% DownsideCORTCorcept Therapeutics 3.00Buy$138.2593.68% UpsideCurrent Analyst Ratings BreakdownLatest AIMT, BPMC, CORT, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BBIOBridgeBio PharmaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$49.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/9/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $56.006/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/ABBIOBridgeBio Pharma$221.90M35.71N/AN/A($7.71) per share-5.41BPMCBlueprint Medicines$562.12M14.73N/AN/A$4.70 per share27.28CORTCorcept Therapeutics$675.04M11.21$1.24 per share57.47$6.49 per share11.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/ABBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A197.23N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)CORTCorcept Therapeutics$141.21M$1.1661.5338.58N/A19.33%20.40%16.64%8/4/2025 (Estimated)Latest AIMT, BPMC, CORT, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40BBIOBridgeBio PharmaN/A4.574.54BPMCBlueprint Medicines1.012.802.75CORTCorcept TherapeuticsN/A3.072.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%BBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/ACORTCorcept Therapeutics93.61%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%BBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%CORTCorcept Therapeutics20.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableCORTCorcept Therapeutics300106.04 million83.99 millionOptionableAIMT, BPMC, CORT, and BBIO HeadlinesRecent News About These CompaniesInsider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics StockJune 19 at 1:53 PM | benzinga.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Boston Trust Walden CorpJune 19 at 6:15 AM | marketbeat.comCWA Asset Management Group LLC Increases Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 19 at 5:15 AM | marketbeat.comTop Executive Sells Thousands in Corcept Therapeutics Stock!June 18, 2025 | tipranks.comRoman Butler Fullerton & Co. Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 18, 2025 | marketbeat.comDazucorilant significantly extends survival in Phase 2 ALS trialJune 16, 2025 | alsnewstoday.comCampbell Newman Asset Management Inc. Sells 16,142 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)June 14, 2025 | marketbeat.comGoldstone Financial Group LLC Acquires Shares of 4,786 Corcept Therapeutics Incorporated (NASDAQ:CORT)June 14, 2025 | marketbeat.comCorcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force HiringJune 13, 2025 | seekingalpha.comMajor Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $0June 13, 2025 | benzinga.comDaniel N. Swisher, Jr. Sells 2,200 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) StockJune 13, 2025 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by SG Americas Securities LLCJune 13, 2025 | marketbeat.comPallas Capital Advisors LLC Purchases Shares of 4,014 Corcept Therapeutics Incorporated (NASDAQ:CORT)June 13, 2025 | marketbeat.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells 2,200 Shares of StockJune 12, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $1,448,400.00 in StockJune 12, 2025 | marketbeat.comInsider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT)June 12, 2025 | gurufocus.comFirst Citizens Bank & Trust Co. Buys New Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 11, 2025 | marketbeat.comBridge City Capital LLC Has $4.80 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 9, 2025 | marketbeat.comTealwood Asset Management Inc. Invests $2.26 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 7, 2025 | marketbeat.comMixed Phase II results for Corcept’s dazucorilantJune 7, 2025 | thepharmaletter.comIntellectus Partners LLC Has $4.80 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)June 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMT, BPMC, CORT, and BBIO Company DescriptionsAimmune Therapeutics NASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.BridgeBio Pharma NASDAQ:BBIO$41.73 +1.73 (+4.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$41.60 -0.13 (-0.31%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMC$128.20 +0.08 (+0.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$128.18 -0.01 (-0.01%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Corcept Therapeutics NASDAQ:CORT$71.38 +0.14 (+0.20%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$71.16 -0.22 (-0.31%) As of 06/20/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
